Seizure, fever, and immune thrombocytopenia purpura (ITP) are the types of adverse events associated with vaccines for measles.
An investigation was done to check whether the measles-mumps-rubella-varicella (MMRV) is riskier than the separate measles-mumps-rubella (MMR) and varicella (MMR + V) and if it elevates the risk for additional safety outcomes.
Study children were aged 12 to 23 months in the Vaccine Safety Datalink from 2000 to 2012. The number of doses evaluated for MMRV was 123 200 and 584 987 for MMR + V respectively.
Seven outcomes (anaphylaxis, ITP, ataxia, arthritis, meningitis/encephalitis, acute disseminated encephalomyelitis, and Kawasaki disease) were analysed and compared with the vaccines.
There was no significant difference between MMRV with MMR + V as the outcomes had few or zero post vaccination events.
The study did not identify any new safety concerns comparing MMRV with MMR + V or after either the MMRV or the MMR + V vaccine.
The study reassures that these outcomes are unlikely after either vaccine.